Base Therapeutics (shanghai) Co., Ltd.
Clinical trials sponsored by Base Therapeutics (shanghai) Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New cell therapy takes on Hard-to-Treat cancers Results expected Jun 2027 (estimated)
- Engineered immune cells take on Drug-Resistant lung cancer in first human trial Results expected Jul 2027 (estimated)
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase trial tests a new cell therapy called NK521 for people with advanced liver cancer (hepatocellular carcinoma) or ovarian cancer that has not responded to standard treatments. NK521 are natural killer (NK) cells that have been gene-edited to remove three proteins t…
Early phase 1 • Sponsor: Base Therapeutics (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New cell therapy takes on Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase trial will test NK510, a cell therapy, in 15 people with advanced stomach or colorectal cancer that has come back or not responded to at least two prior treatments. NK510 is given through an IV or directly into the abdomen. The main goals are to check safety and …
Early phase 1 • Sponsor: Base Therapeutics (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 15:44 UTC